Peg-Interferon Alfa 2-b Related Cellulitis in a 40 Years Man
Background: Pegylated interferon and ribavirin are currently one of the accepted treatment for chronic Hepatitis C. Dermatologic complications of interferon have been reported, but to date a few cases of bacterial cellulitis; a rare and severe complication, have been published. Cellulitis is a common infectious process affecting the skin and subcutaneous tissues which results in significant morbidity and holds considerable healthcare costs.
Cases Report: Herein, we report a case of chronic hepatitis C genotype 1a who was on medication since 8 weeks prior to developing leg cellulitis, an uncommon pegylated interferon injection site. Considering no other possible risk factors were found to be in favor of bacterial cellulitis, our case is unique in its kind. Some reports reveal necrotizing vasculitis as basis for cutaneous lesions, which could be due to the high concentrations of drug at the injection site, a toxic effect of the diluents, or an immunological reaction.
Conclusion: According to the latter mechanism patients could develop bacterial cellulitis in their different organs. Conclusively, we propose the hypothesis of a possible association between cellulitis to occur at any site as the complication of pegylated interferon Alfa 2b and would highlight the role of a careful skin examination that could be an asset in preventing local skin infections.
Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology. 2001;34:395-403.
Zeuzem S,Feinman V, Rasenack J, Heathcote J, Lai My, Gane E, O’grady J, et al. Peginterferon Alfa-2a In Patients With Chronic Hepatitis C. N Engl J Med. 2000;343:1666-72.
Ward P, Kugelmas M. Using Pegylated Interferon and Ribavirin to Treat Patients with Chronic Hepatitis C, American Family Physician. 2005;72(4):655-62.
Sickler JB, Simmons RA, Cobb DK, Sherman KE. Cutaneous necrosis associated with interferon alfa-2b. Am J Gastroenterol. 1998;93:463-4.
Krainick U, Kantarjian H, Broussar DS, Talpaz M. Local cutaneous necrotizing lesions associated wiyh interferon injections. J Interferon Cytokine Res. 1998;18:823-7.
Cnudde F, Gharakhanian S, Luboinski J, Dry J, Rozenbaum W. Cutaneous local necrosis following interferon injections. Int J Dermatol. 1991;30:147.
Oeda E, Shinohara K. Cutaneous necrosis caused by injection of alfa interferon in patient with chronic myelogenous leukemia. Am J Hematol. 1993;44:213-4.
Heinzerling L, Dummer R, Wildberger H, Burg G. Cutaneous ulceration after injection of polyethylene-glycol-modified interferon alfa associated with visual disturbances in a melanoma patient. Dermatology. 2000;201:154-7.
Lanternier F, Bon C, Memain N, Roulot D, Lortholary O. Severe streptococcal cellulitis after subcutaneous pegylated interferon alfa-2b in a diabetic patient. Gastroenterol Clin Biol 2004; 28: 1294-1303
PEG-Intron (Peginterferon alfa-2b) powder for injection (package information). Kenilworth, NJ: Schering Corp., March 2003. Accessed online July 25, 2005, at: http://www.spfiles.com/pipeg-intron.pdf.
The DRG Handbook Comparative Clinical and Financial Benchmarks. 2006, Evanston, IL:Solucient.
Bernard P. Management of common bacterial infections of the skin. Current Opinion in Infectious Diseases. 2008;21:122–8.
Goettsch WG, Bouwes Bavinck JN, Herings RMC. Burden of illness of bacterial cellulitis and erysipelas of the leg in the Netherlands. J Eur Acad Dermatol Venereol. 2006;20:834–839.
Gabillot-Carre´ M, Roujeau JC. Acute bacterial skin infections and cellulitis. Current Opinion in Infectious Diseases. 2007;20:118–23.
Hepburn MJ, Dooley DP, Ellis MW. Alternative diagnoses that often mimic cellulitis. Am Fam Physician. 2003;67(12):2471.
David CV, Chira S, Eells SJ, Ladrigan M, Papier A, Miller LG, Craft N. Diagnostic accuracy in patients admitted to hospitals with cellulitis. Dermatology Online Journal. 2011;17(3):1.
Yu ML, Dai CY, Lee LP, Hsieh MY, Hou NJ, Huang JF, et al. Outcome of chronic hepatitis C patients who required early termination of pegylated interferon-alpha plus ribavirin combination therapy. Antivir Ther. 2006;11(8):1015-9.
El-Serag HB, Anand B, Richardson P, Rabeneck L. Association between Hepatitis C Infection and Other Infectious Diseases: A Case for Targeted Screening? Am J Gastroenterol. 2003;98(1):167-74.
Howell CD, Jeffers LS, Cassidy W, Reddy KR, Hu S, Lee JS. Peginterferon alfa-2a and ribavirin for chronic hepatitis C genotype 1 infections in black patients: safety, tolerability and impact on sustained virologic response. Journal of Viral Hepatitis. 2006;13:371–6.
Ho SB, Aqel B, Dieperink E, Tetrick L, Falck-Ytter Y, Comarmond CA. U.S. Multicenter Pilot Study Of Daily Consensus Interferon (Infergen) Plus Ribavirin For “Difficult-To-Treat” Hcv Genotype 1 Patients: Tolerance and On-Therapy Virologic Response. Hepatology. Aasld Abstracts, October 2007, abstract number 1332, 830A.
Soza A, Everhart JE, Ghany MG, Doo E, Heller T, Promrat K, et al. Neutropenia During Combination Therapy of Interferon Alfa and Ribavirin for Chronic Hepatitis C. Hepatology. 2002;36:1273-9.
E Health Me. 2011 [cited November 25th]; Available from: http://www.HealthMe.com.
Lanternier F, Bon C, Memain N, Roulot D, Lortholary O. Severe streptococcal cellulitis after subcutaneous pegylated interferon alfa-2B in a diabetic patient. Gastroentérologie Clinique et Biologique. 2004;28:1294-303.